Drug Profile

CXL 1020

Alternative Names: CXL-1020

Latest Information Update: 25 Sep 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cardioxyl Pharmaceuticals; Johns Hopkins University
Developer Cardioxyl Pharmaceuticals
Class Heart failure therapies; Nitrogen oxides; Small molecules
Mechanism of Action Nitric oxide donors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Acute heart failure

Most Recent Events

10 Feb 2015 Discontinued - Phase-II for Acute heart failure (In the elderly, In adults) in USA (IV)
20 Nov 2014 Preclinical pharmacodynamics data in Heart failure presented at the 87th Annual Scientific Sessions of the American Heart Association (AHA-2014)
28 Oct 2013 Interim efficacy data from a phase II trial in Acute decompensated heart failure released by Cardioxyl Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com